| P50 | author | Dafna D. Gladman | Q37605821 |
| | Iain McInnes | Q41687181 |
| | Michael Elashoff | Q77987421 |
| | Arthur Kavanaugh | Q93106996 |
| P2093 | author name string | Michael Mack | |
| | Philip J Mease | |
| | Juan J Gomez-Reino | |
| | Gerald G Krueger | |
| | Sudha Visvanathan | |
| | Kim Papp | |
| | Anna Beutler | |
| | Frederick T Murphy | |
| | Carrie L Wagner | |
| P2860 | cites work | TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor | Q28176724 |
| | Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment | Q28345197 |
| | Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo | Q28475485 |
| | Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad | Q33614786 |
| | Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion | Q34153144 |
| | Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study | Q34613963 |
| | Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Q35579437 |
| | Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. | Q35637875 |
| | Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment | Q35638455 |
| | Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab | Q35896663 |
| | IL-17 induces the production of IL-16 in rheumatoid arthritis | Q37184922 |
| | TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade | Q37463943 |
| | What's new in our understanding of the role of adipokines in rheumatic diseases? | Q37909903 |
| | Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. | Q44076079 |
| | Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study | Q46297341 |
| | A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs | Q47772154 |
| | Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. | Q51773253 |
| | Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors | Q56974069 |
| | Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis | Q73587996 |
| | Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels | Q83057471 |
| | Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis | Q85036491 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| P304 | page(s) | 83-88 | |
| P577 | publication date | 2012-09-12 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab | |
| P478 | volume | 72 | |